Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zelatriazin
- Development stage
- Discontinued
- Lead developer
- Neurocrine Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zelatriazin (TAK-041; NBI-1065846) is a potent, selective, orally active small molecule agonist of the G protein-coupled receptor 139 (GPR139). Originally developed by Takeda Pharmaceutical Company and later licensed to Neurocrine Biosciences, the compound was investigated as an adjunctive therapy to antipsychotics for the treatment of negative symptoms and cognitive impairment associated with schizophrenia, specifically targeting motivational anhedonia. GPR139 is highly expressed in the habenula, a brain region involved in reward processing and motivation. In 2024, Neurocrine Biosciences announced the termination of its license agreement with Takeda for the development of this compound, effective April 2025.
- Brand names
- zelatriazin
- Other names
- zelatriazin
02
Targets
GPR139 (G protein-coupled receptor 139)
Beyond the preview
Go deeper on zelatriazin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zelatriazin.